Image Source: AsiaOne
Moleac’s NeuroAiD™II Improves Post-Concussion Symptoms, Quality of Life, and Mood after a Mild Traumatic Brain Injury GlobeNewswire December 05, 2023 With its targeted multimodal approach, NeuroAiD™II offers a broad range of therapeutic benefits to TBI patients.NeuroAiD™II was well-tolerated by TBI patients with a favourable safety profile. SINGAPORE, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Moleac announced promising results from the SAMURAI double-blind study in patients with mild traumatic brain injury (mTBI) receiving a 6-month course of NeuroAiD™II. In the study, the NeuroAiD™II group showed significant improvement in their post-concussion symptoms, quality of life and mood, compared to those in the placebo group.
Source: AsiaOne